BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weersink RA, Taxis K, Drenth JPH, Houben E, Metselaar HJ, Borgsteede SD. Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study. Drug Saf 2019;42:539-46. [PMID: 30357649 DOI: 10.1007/s40264-018-0744-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Strickler AG, Shah P, Bajaj S, Mizuguchi R, Nijhawan RI, Odueyungbo M, Rossi A, Ratner D. Preventing and managing complications in dermatologic surgery: Procedural and postsurgical concerns. J Am Acad Dermatol 2021;84:895-903. [PMID: 33493570 DOI: 10.1016/j.jaad.2021.01.037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wei F, Guo L, Xu Y, Chen D, Gong M. Comparative Pharmacokinetic Study of Taxifolin after Oral Administration of Fructus Polygoni Orientalis Extract in Normal and Fibrotic Rats by UPLC-MS/MS. Evid Based Complement Alternat Med 2019;2019:9348075. [PMID: 31976002 DOI: 10.1155/2019/9348075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
3 Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc 2019;82:756-61. [PMID: 31335628 DOI: 10.1097/JCMA.0000000000000157] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Mohammed BS, Aidoo M. Drug Treatment of Patients with Liver Cirrhosis in a Tertiary Hospital in Northern Ghana: Does It Comply with Recommended Guidelines? Int J Hepatol 2020;2020:9750194. [PMID: 32550025 DOI: 10.1155/2020/9750194] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 García-Cortés M, García-García A. Management of Pharmacologic Adverse Effects in Advanced Liver Disease. Clin Drug Investig 2022. [PMID: 35522395 DOI: 10.1007/s40261-022-01150-w] [Reference Citation Analysis]
6 Hayward KL, Weersink RA. Improving Medication-Related Outcomes in Chronic Liver Disease. Hepatol Commun 2020;4:1562-77. [PMID: 33163829 DOI: 10.1002/hep4.1612] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ferreira V, Vincelette C, Mathieu A. Joint Efforts to Ensure Evidence-Based Decisions by Clinicians in Drug Adjustment for Chronic Liver Disease Populations. Hepatol Commun 2021;5:713-4. [PMID: 33860128 DOI: 10.1002/hep4.1664] [Reference Citation Analysis]
8 Hayward KL, Valery PC, Patel PJ, Li C, Horsfall LU, Wright PL, Tallis CJ, Stuart KA, David M, Irvine KM, Cottrell N, Martin JH, Powell EE. Medication Discrepancies and Regimen Complexity in Decompensated Cirrhosis: Implications for Medication Safety. Pharmaceuticals (Basel) 2021;14:1207. [PMID: 34959611 DOI: 10.3390/ph14121207] [Reference Citation Analysis]
9 Weersink RA, Abadier M, de Boer A, Taxis K, Borgsteede SD. Medication safety in patients with hepatic impairment: A survey of community pharmacists' knowledge level and their practice in caring for these patients. Br J Clin Pharmacol 2020;86:763-70. [PMID: 31756269 DOI: 10.1111/bcp.14177] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Rubin JB, Lai JC, Shui AM, Hohmann SF, Auerbach A. Patterns of Inpatient Opioid Use and Related Adverse Events Among Patients With Cirrhosis: A Propensity-Matched Analysis. Hepatol Commun 2021;5:1081-94. [PMID: 34141991 DOI: 10.1002/hep4.1694] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]